Treprostinil is under clinical development by Liquidia Technologies and currently in Pre-Registration for Pulmonary Hypertension. According to GlobalData, Pre-Registration drugs for Pulmonary Hypertension have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Treprostinil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Treprostinil overview
Treprostinil (Yutrepia) is a prostacyclin analog acts as antihypertensive agent. It is formulated as dry powder for inhalation route of administration (DPI). Yutrepia is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms.
Treprostinil (Yutrepia) is under development for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). It acts by targeting prostacyclin receptor.
Liquidia Technologies overview
Liquidia Technologies, a subsidiary of Liquidia Corp, is a biopharmaceutical company that develops and supplies human therapeutics devices for pulmonary hypertension. The company is headquartered in Durham, North Carolina, the US.
For a complete picture of Treprostinil’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
